Does gefitinib prolong the survival of adenocarcinoma patients against non-adeno non-small cell lung cancer? A retrospective study.

Does gefitinib prolong the survival of adenocarcinoma patients against non-adeno non-small cell lung cancer? A retrospective study. - A retrospective survival analysis of patients in non-small cell lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001263

Enrollment

1400

Registered

2008-07-23

Start date

2008-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced non-small cell lung cancer patients who treated with initial chemotherapy during Junuary 1st 2004 to December 31st 2005.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results